中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.021 seconds)

    TM7SF3 COMPOSITION FOR DIAGNOSING LIVER CANCER, DIAGNOSTIC KIT CONTAINING ANTI-TM7SF3 ANTIBODIES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER
    1.
    发明申请
    TM7SF3 COMPOSITION FOR DIAGNOSING LIVER CANCER, DIAGNOSTIC KIT CONTAINING ANTI-TM7SF3 ANTIBODIES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER 审中-公开
    用于诊断肝癌的TM7SF3组合物，含有抗TM7SF3抗体的诊断试剂盒和用于预防或治疗肝癌的药物组合物

    公开(公告)号：WO2010098613A9

    公开(公告)日：2011-03-03

    申请号：PCT/KR2010001222

    申请日：2010-02-26

    Applicant: POSTECH ACAD IND FOUND ,  SUNG YOUNG CHUL ,  YANG SE HWAN ,  CHOI SO YOUNG ,  LEE JI YEUNG ,  KIM SAE WON

    Inventor： SUNG YOUNG CHUL ,  YANG SE HWAN ,  CHOI SO YOUNG ,  LEE JI YEUNG ,  KIM SAE WON

    IPC: G01N33/574 ,  A61K39/395 ,  A61P35/00 ,  G01N33/53

    CPC classification number: G01N33/57438 ,  C07K16/303

    Abstract: The present invention relates to a composition for diagnosing liver cancer containing TM7SF3 as an active ingredient, a kit for diagnosing liver cancer with anti-TM7SF3 antibodies as reagent, and a pharmaceutical composition for preventing or treating liver cancer containing the anti-TM7SF3 antibodies as an active ingredient. The TM7SF3 protein is rarely expressed in liver tissue of a healthy person, but is specifically over-expressed in malignant hepatic tissue of liver cancer patients. As diagnosis or prognosis of liver cancer is thus predictable, the TM7SF protein can be used as a marker for diagnosing liver cancer. In addition, the anti-TM7SE3 antibodies of the present invention specifically bind with an extracellular domain of the TTM7SF3, and respond to this particular liver cell line. Therefore, the anti-TM7SE3 antibodies selectively induce apoptosis of only cancer cells caused by IM7SF3 over-expression, and can thus be used in preventing or treating liver cancer.

    Abstract translation: 本发明涉及用于诊断含有TM7SF3作为活性成分的肝癌的组合物，用抗TM7SF3抗体作为试剂诊断肝癌的试剂盒，以及用于预防或治疗含有抗TM7SF3抗体的肝癌的药物组合物 有效成分。 TM7SF3蛋白很少在健康人的肝组织中表达，但在肝癌患者的恶性肝组织中特异性地过表达。 由于肝癌的诊断或预后因此可预测，TM7SF蛋白可用作诊断肝癌的标志物。 此外，本发明的抗TM7SE3抗体与TTM7SF3的细胞外结构域特异性结合，并对该特定肝细胞系作出反应。 因此，抗TM7SE3抗体选择性诱导仅由IM7SF3过度表达引起的癌细胞的凋亡，因此可用于预防或治疗肝癌。

    PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT OR METASTASIS INHIBITION CONTAINING EXPRESSION OR ACTIVATION INHIBITORS OF MAP7D2 PROTEIN, NOVEL CANCER THERAPEUTIC TARGET
    5.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT OR METASTASIS INHIBITION CONTAINING EXPRESSION OR ACTIVATION INHIBITORS OF MAP7D2 PROTEIN, NOVEL CANCER THERAPEUTIC TARGET 审中-公开
    含有MAP7D2蛋白，新型癌症治疗目标的表达或激活抑制剂的癌症治疗或METASTASIS抑制剂的药物组合物

    公开(公告)号：WO2012115437A3

    公开(公告)日：2012-12-20

    申请号：PCT/KR2012001316

    申请日：2012-02-21

    Applicant: KOREA RES INST OF BIOSCIENCE ,  KWON KI SUN ,  KIM SEON-YOUNG ,  CHOI SO YOUNG ,  DHO SO HEE ,  PARK SUNG SUP ,  LEE KWANG PYO

    Inventor： KWON KI SUN ,  KIM SEON-YOUNG ,  CHOI SO YOUNG ,  DHO SO HEE ,  PARK SUNG SUP ,  LEE KWANG PYO

    IPC: A61K39/395 ,  A61K38/16 ,  A61K38/17 ,  A61K48/00 ,  A61P35/00

    CPC classification number: C12N15/113 ,  C12N2310/14

    Abstract: The present invention relates to the pharmaceutical composition for cancer treatment or metastasis inhibition containing expression or activation inhibitors of MAP7D2 protein as an active ingredient. More specifically a novel anti-cancer therapeutic target has been discovered using data-mining techniques by building a large-scale gene expression database of human cancer tissues, and, based on the gene expression profiles of cancer cell lines, appropriate cancer cell lines were selected and experimentally verified through the inhibition of candidate target genes. Through these, MAP7D2 has been verified as a novel potential anti-cancer target which is over-expressed in a variety of cancer tissues or cells, such as cancer tissues or cells of the kidney, lung, large-intestine, ovary, stomach and liver, and inhibition of which impedes the growth, movement, infiltration and metastasis of cancer cells, thereby leading to cell destruction. As such, expression levels of MAP7D2 can be useful as a diagnostic marker for cancer and an MAP7D2 protein expression or activation inhibitor can be used as an active ingredient in a pharmaceutical composition for cancer treatment or metastasis inhibition.

    Abstract translation: 本发明涉及含有MAP7D2蛋白的表达或活化抑制剂作为活性成分的用于癌症治疗或转移抑制的药物组合物。 更具体地，通过构建人癌组织的大规模基因表达数据库，已经使用数据挖掘技术发现了新的抗癌治疗靶，并且基于癌细胞系的基因表达谱，选择合适的癌细胞系 并通过抑制候选靶基因进行实验验证。 通过这些，MAP7D2已经被验证为一种新的潜在的抗癌靶，其在多种癌组织或细胞如癌组织或肾，肺，大肠，卵巢，胃和肝中的细胞中过度表达 ，其抑制作用阻碍癌细胞的生长，运动，浸润和转移，从而导致细胞破坏。 因此，MAP7D2的表达水平可用作癌症的诊断标志物，并且MAP7D2蛋白表达或活化抑制剂可用作用于癌症治疗或转移抑制的药物组合物中的活性成分。

    TM7SF3 COMPOSITION FOR DIAGNOSING LIVER CANCER, DIAGNOSTIC KIT CONTAINING ANTI-TM7SF3 ANTIBODIES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER
    7.
    发明申请
    TM7SF3 COMPOSITION FOR DIAGNOSING LIVER CANCER, DIAGNOSTIC KIT CONTAINING ANTI-TM7SF3 ANTIBODIES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER 审中-公开
    用于诊断肝癌的TM7SF3组合物，含有抗TM7SF3抗体的诊断试剂盒和用于预防或治疗肝癌的药物组合物

    公开(公告)号：WO2010098613A2

    公开(公告)日：2010-09-02

    申请号：PCT/KR2010001222

    申请日：2010-02-26

    Applicant: POSTECH ACAD IND FOUND ,  SUNG YOUNG CHUL ,  YANG SE HWAN ,  CHOI SO YOUNG ,  LEE JI YEUNG ,  KIM SAE WON

    Inventor： SUNG YOUNG CHUL ,  YANG SE HWAN ,  CHOI SO YOUNG ,  LEE JI YEUNG ,  KIM SAE WON

    IPC: G01N33/574 ,  A61K39/395 ,  A61P35/00 ,  G01N33/53

    CPC classification number: G01N33/57438 ,  C07K16/303

    Abstract: The present invention relates to a composition for diagnosing liver cancer containing TM7SF3 as an active ingredient, a kit for diagnosing liver cancer with anti-TM7SF3 antibodies as reagent, and a pharmaceutical composition for preventing or treating liver cancer containing the anti-TM7SF3 antibodies as an active ingredient. The TM7SF3 protein is rarely expressed in liver tissue of a healthy person, but is specifically over-expressed in malignant hepatic tissue of liver cancer patients. As diagnosis or prognosis of liver cancer is thus predictable, the TM7SF protein can be used as a marker for diagnosing liver cancer. In addition, the anti-TM7SE3 antibodies of the present invention specifically bind with an extracellular domain of the TTM7SF3, and respond to this particular liver cell line. Therefore, the anti-TM7SE3 antibodies selectively induce apoptosis of only cancer cells caused by IM7SF3 over-expression, and can thus be used in preventing or treating liver cancer.

    Abstract translation: 本发明涉及用于诊断含有TM7SF3作为活性成分的肝癌的组合物，用抗TM7SF3抗体作为试剂诊断肝癌的试剂盒，以及用于预防或治疗含有抗TM7SF3抗体的肝癌的药物组合物 有效成分。 TM7SF3蛋白很少在健康人的肝组织中表达，但在肝癌患者的恶性肝组织中特异性地过表达。 由于肝癌的诊断或预后因此可预测，TM7SF蛋白可用作诊断肝癌的标志物。 此外，本发明的抗TM7SE3抗体与TTM7SF3的细胞外结构域特异性结合，并对该特定肝细胞系作出反应。 因此，抗TM7SE3抗体选择性诱导仅由IM7SF3过度表达引起的癌细胞的凋亡，因此可用于预防或治疗肝癌。

Patent Agency Ranking